Equities Analysts Set Expectations for Adaptimmune Therapeutics PLC -‘s FY2018 Earnings (ADAP)

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) – Investment analysts at SunTrust Banks increased their FY2018 earnings estimates for shares of Adaptimmune Therapeutics in a research report issued to clients and investors on Tuesday, November 6th. SunTrust Banks analyst P. Lawson now expects that the biotechnology company will post earnings of ($0.89) per share for the year, up from their previous estimate of ($0.96). SunTrust Banks also issued estimates for Adaptimmune Therapeutics’ Q4 2018 earnings at ($0.26) EPS, FY2019 earnings at ($1.16) EPS, FY2020 earnings at ($1.41) EPS, FY2021 earnings at ($0.94) EPS and FY2022 earnings at ($0.16) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.09. The company had revenue of $40.79 million during the quarter, compared to the consensus estimate of $29.41 million. Adaptimmune Therapeutics had a negative return on equity of 41.63% and a negative net margin of 139.57%.

Several other research analysts also recently issued reports on the company. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Zacks Investment Research downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 6th. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Tuesday, November 6th. Finally, Raymond James cut their price target on Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, October 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $15.44.

NASDAQ:ADAP opened at $6.18 on Friday. The firm has a market cap of $627.87 million, a PE ratio of -7.73 and a beta of 2.02. Adaptimmune Therapeutics has a 52-week low of $5.73 and a 52-week high of $14.63.

In related news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of Adaptimmune Therapeutics stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $13.79, for a total transaction of $344,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ali Behbahani acquired 12,000,000 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were bought at an average price of $1.67 per share, with a total value of $20,040,000.00. The disclosure for this purchase can be found here. Insiders own 26.47% of the company’s stock.

A number of institutional investors have recently bought and sold shares of ADAP. BNP Paribas Arbitrage SA purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter worth about $122,000. BB&T Securities LLC purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter worth about $128,000. Jane Street Group LLC purchased a new stake in Adaptimmune Therapeutics during the 1st quarter worth about $168,000. Trexquant Investment LP purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter worth about $178,000. Finally, Trellus Management Company LLC purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter worth about $195,000. Hedge funds and other institutional investors own 58.99% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

See Also: Bear Market

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply